SynthesisAnnals of medicine2025
Extracorporeal shock wave therapy for peripheral arterial disease-related intermittent claudication: a systematic review and meta-analysis.
Synthesis in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntermittent claudication (IC) is a common manifestation of peripheral arterial disease. This study evaluates the efficacy of extracorporeal shock wave therapy (ESWT), a non-invasive treatment, for patients with IC.
methodsA systematic review and meta-analysis of four major databases (PubMed, Embase, Cochrane Library, Web of Science) was conducted through March 2025. Eight studies met inclusion criteria for the analysis, which was performed using Review Manager 5.4 with evidence strength assessed by the GRADE system.
resultsThe analysis included eight studies with a total of 332 patients (mean age >50 years, 67.5% male). Compared to placebo, ESWT demonstrated significant improvements in functional outcomes. It led to substantial increases in both Pain-Free Walking Distance (MD=26.53,
conclusionESWT is associated with improved walking distance and quality of life in patients with IC. These findings require cautious interpretation due to the limited number of studies and small sample sizes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.